121 Participants Needed

Veliparib + Dinaciclib for Advanced Cancers

Recruiting at 1 trial location
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase I trial studies the side effects and the best dose of veliparib and dinaciclib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment. Veliparib and dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, you cannot receive any other anti-cancer therapy while on this study, except for certain supportive care medications. If you are on a potent CYP3A4 inhibitor or inducer, you may need to switch to another medication.

Is the combination of Veliparib and Dinaciclib safe for humans?

Veliparib has been studied in combination with other drugs like carboplatin and gemcitabine in various cancers, and these studies aimed to find the safest dose and identify any serious side effects. While specific safety data for Veliparib combined with Dinaciclib isn't provided, Veliparib has been evaluated for safety in other combinations, suggesting it has been considered safe enough to test in humans.12345

What makes the drug combination of Veliparib and Dinaciclib unique for treating advanced cancers?

The combination of Veliparib and Dinaciclib is unique because Veliparib is a PARP inhibitor that helps prevent cancer cells from repairing their DNA, making them more sensitive to treatment, while Dinaciclib is a cyclin-dependent kinase inhibitor that disrupts cancer cell division. This dual approach targets cancer cells in two different ways, which may enhance treatment effectiveness compared to using either drug alone.16789

Who Is on the Research Team?

Geoffrey Shapiro, MD, PhD - Dana-Farber ...

Geoffrey I. Shapiro

Principal Investigator

Dana-Farber Cancer Institute

Are You a Good Fit for This Trial?

This trial is for adults with advanced solid tumors that have spread and are not curable. Participants must have a certain level of blood counts, organ function, and no recent chemotherapy or radiation. They should be able to swallow pills, may have had prior treatments but need to recover from them, agree to use contraception if they can bear children, and provide tissue samples. People with uncontrolled illnesses or who are pregnant/nursing cannot join.

Inclusion Criteria

Absolute neutrophil count >= 1,500/mm^3
I haven't taken any experimental drugs or immunotherapies for the last 3 weeks.
Ability to understand and the willingness to sign a written informed consent document; subjects must be willing to adhere to dose and visit schedules
See 18 more

Exclusion Criteria

I do not have any severe illnesses or social situations that would stop me from following the study's requirements.
I am not pregnant or breastfeeding.
I have not had a seizure in the last three months.
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part 1A

Patients receive veliparib orally twice daily on days 1-28 and dinaciclib intravenously over 2 hours on days 8 and 22. Cycles repeat every 28 days.

28 days per cycle

Treatment Part 1B

Patients receive veliparib and dinaciclib as in Part 1A. Cycles repeat every 28 days.

28 days per cycle

Treatment Part 1C

Patients receive veliparib orally twice daily on days 1-7 of cycle 0, then veliparib on days 1-21 and dinaciclib on days 1, 4, 8, and 11 or days 1 and 8. Cycles repeat every 21 days.

21 days per cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment completion.

Every 3 months

What Are the Treatments Tested in This Trial?

Interventions

  • Veliparib and Dinaciclib
Trial Overview The trial is testing the combination of two drugs: Veliparib (ABT-888) and Dinaciclib (SCH727965), which might block enzymes that help tumor cells grow. It's in phase I to find out the safest dose with the least side effects for patients whose cancer has spread widely.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Treatment (veliparib and dinaciclib)Experimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

In the BROCADE3 trial, crossover treatment with veliparib after disease progression on placebo plus carboplatin/paclitaxel showed limited antitumor activity, with only 16% of patients responding, particularly those with longer platinum-free intervals (PFI ≥180 days).
BRCA reversion mutations were found in some patients and were associated with shorter treatment duration and reduced efficacy of veliparib, suggesting that these mutations may contribute to resistance against the drug.
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).Puhalla, SL., Diéras, V., Arun, BK., et al.[2023]

Citations

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. [2022]
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. [2018]
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). [2023]
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. [2023]
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. [2022]
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. [2018]
Veliparib for the treatment of solid malignancies. [2022]
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. [2021]
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security